Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Inclusion Criteria:

Arm-1: Early stage (II-III), locally advanced or advanced ER-positive and HER2-negative Breast Cancer

Signed, written, voluntary, and informed consent
Histological confirmation of early stage (II-III) locally advanced or advanced ER positive and HER2 negative breast cancer
Tumor DNA sequencing has been completed by selected NGS vendor(s) at the time of or prior to treatment initiation
Female participants between 18 - 85 years of age
ECOG performance status that is equal to 0 or 1 at the time of screening.
Must be willing to provide blood for immune profile analysis on study enrollment and at specified study time points
Must be willing and able to perform stool sample collection
Participants due to receive standard of care CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) in combination with endocrine therapy

Exclusion Criteria:

Arm-1: Early stage (II-III), locally advanced or advanced ER-positive and HER2-negative Breast Cancer

Adult males
Mental incapacity, as determined by an investigator
Participant is pregnant, breastfeeding, or plans to become pregnant during the course of the study
Experiencing active brain metastasis/metastases
Active participation in an immuno-oncology or interventional clinical trial
Participation in any experimental trial in the 3 months prior to screening
Participant has relapsed on prior endocrine therapy for this instance of cancer, or has discontinued any prior adjuvant endocrine therapy within 6 months of screening
History of inflammatory bowel disease, chronic diarrhea or malabsorption syndromes, or significant prior bowel resection as judged by the study investigator
Use of immunosuppressants, including steroids, within 4 weeks of the first sample collection
Oral or intravenous antibiotic usage within 3 months of the first sample collection